FAAH2

Summary

FAAH2 (fatty acid amide hydrolase 2, HGNC:26440) is a protein-coding gene on chromosome Xp11.21, encoding Fatty-acid amide hydrolase 2 (Q6GMR7). Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regul….

This gene encodes a fatty acid amide hydrolase that shares a conserved protein motif with the amidase signature family of enzymes. The encoded enzyme is able to catalyze the hydrolysis of a broad range of bioactive lipids, including those from the three main classes of fatty acid amides; N-acylethanolamines, fatty acid primary amides and N-acyl amino acids. This enzyme has a preference for monounsaturated acyl chains as a substrate. Alternate splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 158584 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autism spectrum disorder (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 268 total — 2 pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_174912

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26440
Approved symbol	FAAH2
Name	fatty acid amide hydrolase 2
Location	Xp11.21
Locus type	gene with protein product
Status	Approved
Aliases	RP11-479E16.1, FLJ31204, FAAH-2
Ensembl gene	ENSG00000165591
Ensembl biotype	protein_coding
OMIM	300654
Entrez	158584

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 11 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000374900, ENST00000465623, ENST00000491179, ENST00000886034, ENST00000886035, ENST00000886036, ENST00000886037, ENST00000886038, ENST00000886039, ENST00000886040, ENST00000928697, ENST00000928698, ENST00000972153

RefSeq mRNA: 3 — MANE Select: NM_174912 NM_001353840, NM_001353841, NM_174912

CCDS: CCDS14375

Canonical transcript exons

ENST00000374900 — 11 exons

Exon	Start	End
ENSE00001094475	57380912	57381029
ENSE00001094485	57378651	57378786
ENSE00001094487	57341271	57341390
ENSE00001094490	57292498	57292580
ENSE00001094492	57331598	57331807
ENSE00001094496	57431918	57432037
ENSE00001306973	57310593	57310729
ENSE00001465068	57286706	57287017
ENSE00001897083	57488757	57489193
ENSE00003558174	57448524	57448718
ENSE00003649775	57446928	57447039

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 91.62.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0167 / max 137.0702, expressed in 655 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196513	1.5578	543
196512	0.8013	254
196511	0.6576	265

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	91.62	gold quality
body of pancreas	UBERON:0001150	91.18	gold quality
right lobe of liver	UBERON:0001114	89.88	gold quality
epithelial cell of pancreas	CL:0000083	89.81	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	89.33	gold quality
pancreas	UBERON:0001264	88.94	gold quality
pituitary gland	UBERON:0000007	88.81	gold quality
adenohypophysis	UBERON:0002196	88.63	gold quality
islet of Langerhans	UBERON:0000006	88.28	gold quality
skin of abdomen	UBERON:0001416	87.65	gold quality
skin of leg	UBERON:0001511	86.97	gold quality
lower esophagus mucosa	UBERON:0035834	86.10	gold quality
zone of skin	UBERON:0000014	85.16	gold quality
minor salivary gland	UBERON:0001830	84.80	gold quality
mucosa of transverse colon	UBERON:0004991	84.17	gold quality
epithelium of nasopharynx	UBERON:0001951	83.14	gold quality
mouth mucosa	UBERON:0003729	83.03	gold quality
prostate gland	UBERON:0002367	83.00	gold quality
cerebellar hemisphere	UBERON:0002245	82.84	gold quality
cerebellar cortex	UBERON:0002129	82.69	gold quality
nasal cavity epithelium	UBERON:0005384	82.03	silver quality
saliva-secreting gland	UBERON:0001044	81.96	gold quality
esophagus mucosa	UBERON:0002469	81.89	gold quality
right hemisphere of cerebellum	UBERON:0014890	81.81	gold quality
adult mammalian kidney	UBERON:0000082	81.46	gold quality
metanephros cortex	UBERON:0010533	81.30	gold quality
liver	UBERON:0002107	81.26	gold quality
cerebellum	UBERON:0002037	81.21	gold quality
right lobe of thyroid gland	UBERON:0001119	80.73	gold quality
left lobe of thyroid gland	UBERON:0001120	80.46	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.87

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

30 targeting FAAH2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-190B-3P	99.33	68.29	1382
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-138-5P	98.43	70.49	1292
HSA-MIR-338-3P	98.14	67.38	1137
HSA-MIR-676-3P	97.86	65.70	668
HSA-MIR-937-5P	97.43	68.39	667
HSA-MIR-6802-3P	97.29	65.42	613
HSA-MIR-4288	97.11	67.23	1636

Literature-anchored findings (GeneRIF, showing 4)

• FAAH2 is the second membrane-associated AS enzyme in humans that displays FAAH activity (PMID:17015445)
• Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. (PMID:19095868)
• results establish FAAH-2 as a bone fide N-acylethanolamine-catabolizing enzyme and suggest that inactivation is spatially separated in cells of higher mammals (PMID:19926788)
• A male patient with neuropsychiatric disorders attributed to a FAAH2 missense mutation is described. (PMID:25885783)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	faah2a	ENSDARG00000008457
danio_rerio	faah2b	ENSDARG00000054786
drosophila_melanogaster	CG8839	FBGN0033717
caenorhabditis_elegans		WBGENE00013164

Paralogs (2): FAAH (ENSG00000117480), QRSL1 (ENSG00000130348)

Protein

Protein identifiers

Fatty-acid amide hydrolase 2 — Q6GMR7 (reviewed: Q6GMR7)

Alternative names: Amidase domain-containing protein, Anandamide amidohydrolase 2, Oleamide hydrolase 2

All UniProt accessions (2): B2C6G4, Q6GMR7

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling functions of these molecules. Hydrolyzes monounsaturated substrate anandamide preferentially as compared to polyunsaturated substrates.

Subunit / interactions. Homodimer.

Subcellular location. Membrane. Lipid droplet.

Tissue specificity. Expressed in kidney, liver, lung, prostate, heart and ovary.

Activity regulation. Inhibited by O-aryl carbamates and alpha-keto heterocytes.

Similarity. Belongs to the amidase family.

RefSeq proteins (3): NP_001340769, NP_001340770, NP_777572* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR020556	Amidase_CS	Conserved_site
IPR023631	Amidase_dom	Domain
IPR036928	AS_sf	Homologous_superfamily
IPR052739	FAAH2	Family

Pfam: PF01425

Enzyme classification (BRENDA):

• EC 3.5.1.4 — amidase (BRENDA: 67 organisms, 400 substrates, 635 inhibitors, 203 Km, 135 kcat entries)
• EC 3.5.1.99 — fatty acid amide hydrolase (BRENDA: 10 organisms, 176 substrates, 1033 inhibitors, 73 Km, 48 kcat entries)

Substrate kinetics (BRENDA)

120 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ACETAMIDE	0.27–100	25
PROPIONAMIDE	0.0001–88	18
BENZAMIDE	0.0007–7.25	17
ACRYLAMIDE	1.2–93	16
OLEAMIDE	0.007–0.037	11
ISOBUTYRAMIDE	0.0001–7	10
BUTYRAMIDE	0.1–14	7
OLEOYL P-NITROANILIDE	0.012–0.126	7
NICOTINAMIDE	0.3–135.6	6
HEXANAMIDE	0.3–11.08	5
ANANDAMIDE	0.0018–2.78	5
MYRISTOYL P-NITROANILIDE	0.069–0.099	5
NONANOYL P-NITROANILIDE	0.057–0.57	5
2-TOLUAMIDE	0.1–0.3	4
CYCLOMALTOHEXAOSE	0.2–0.3	4

Catalyzed reactions (Rhea), 4 shown:

• N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + H2O = ethanolamine + (5Z,8Z,11Z,14Z)-eicosatetraenoate (RHEA:26136)
• (9Z)-octadecenamide + H2O = (9Z)-octadecenoate + NH4(+) (RHEA:26506)
• N-(9Z-octadecenoyl) ethanolamine + H2O = ethanolamine + (9Z)-octadecenoate (RHEA:45060)
• N-hexadecanoylethanolamine + H2O = ethanolamine + hexadecanoate (RHEA:45064)

UniProt features (6 total): active site 3, chain 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6GMR7-F1	94.08	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 131 (charge relay system); 206 (charge relay system); 230 (acyl-ester intermediate)

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2142753	Arachidonate metabolism

MSigDB gene sets: 35 (showing top): GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_LIPID_CATABOLIC_PROCESS, GOBP_UNSATURATED_FATTY_ACID_METABOLIC_PROCESS, GOBP_ARACHIDONATE_METABOLIC_PROCESS, GOBP_FATTY_ACID_METABOLIC_PROCESS, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_CARBON_NITROGEN_BUT_NOT_PEPTIDE_BONDS_IN_LINEAR_AMIDES, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_CARBON_NITROGEN_BUT_NOT_PEPTIDE_BONDS, chrXp11, GOBP_ICOSANOID_METABOLIC_PROCESS, GOCC_LIPID_DROPLET, REACTOME_ARACHIDONATE_METABOLISM, REACTOME_METABOLISM_OF_LIPIDS

GO Biological Process (3): lipid catabolic process (GO:0016042), arachidonate metabolic process (GO:0019369), lipid metabolic process (GO:0006629)

GO Molecular Function (2): fatty acid amide hydrolase activity (GO:0017064), hydrolase activity (GO:0016787)

GO Cellular Component (2): lipid droplet (GO:0005811), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Fatty acid metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lipid metabolic process	1
catabolic process	1
long-chain fatty acid metabolic process	1
icosanoid metabolic process	1
unsaturated fatty acid metabolic process	1
olefinic compound metabolic process	1
primary metabolic process	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides	1
catalytic activity	1
intracellular membraneless organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1816 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAAH2	NAPEPLD	Q6IQ20	791
FAAH2	NAAA	Q02083	749
FAAH2	ABHD6	Q9BV23	687
FAAH2	MGLL	Q99685	656
FAAH2	DAGLB	Q8NCG7	651
FAAH2	DAGLA	Q9Y4D2	636
FAAH2	ABHD4	Q8TB40	623
FAAH2	ABHD12	Q8N2K0	570
FAAH2	GDE1	Q9NZC3	551
FAAH2	GPR55	Q9Y2T6	547
FAAH2	ZNF765	Q7L2R6	525
FAAH2	TRPV1	Q8NER1	425
FAAH2	ABHD11	Q8NFV4	419
FAAH2	CNR1	P21554	418
FAAH2	GPR119	Q8TDV5	400

IntAct

0 interactions, top by confidence:

BioGRID (3): FAAH2 (Protein-RNA), HNRNPA2B1 (Cross-Linking-MS (XL-MS)), APP (Reconstituted Complex)

ESM2 similar proteins: A0JPE9, A2AJL3, A2VD33, O46504, O75191, P12276, P12785, P13439, P17256, P19096, P31754, Q08D86, Q0IH28, Q0VFE7, Q3MIF4, Q3SYZ6, Q3TNA1, Q4V831, Q4V9P6, Q503J2, Q566S6, Q5M7T9, Q5R979, Q5RFE6, Q5U5V2, Q5XH07, Q5XIG6, Q5ZMJ4, Q64FG0, Q68FH4, Q6DCD1, Q6DH69, Q6GMR7, Q6GP95, Q6NUM9, Q6NUW9, Q6ZS86, Q71SP7, Q7TSQ8, Q80SY6

Diamond homologs: A0A348AXX5, A0KBH9, A0L5G0, A0LSR0, A1V776, A1WVR7, A2S8I9, A3MNR6, A3N4F4, A3NQ45, A3PI90, A4JIT0, A4WUQ2, A5I6Z3, A5UXF9, A7FYL3, A7GIK2, A7NKM0, A8M5E6, A9AC51, A9KBI0, A9N8Z4, A9WCD8, B1INF7, B1K0H7, B1L1G9, B1YPV8, B2A5W7, B2JJW2, B2T1M4, B2U7V7, B3DWT4, B4E7X6, B6IZ25, B6J4H5, B8G974, B8HY89, B8J405, B9KPF8, B9LER8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

268 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	138
Likely benign	14
Benign	5

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1252027	NM_174912.4(FAAH2):c.1175G>A (p.Trp392Ter)	Pathogenic
522688	NM_174912.4(FAAH2):c.267_275+2del	Pathogenic

SpliceAI

2371 predictions. Top by Δscore:

Variant	Effect	Δscore
X:57292494:GCAG:G	acceptor_loss	1.0000
X:57292495:CAGGT:C	acceptor_loss	1.0000
X:57292496:A:AG	acceptor_gain	1.0000
X:57292496:A:G	acceptor_loss	1.0000
X:57292496:AG:A	acceptor_gain	1.0000
X:57292496:AGGT:A	acceptor_gain	1.0000
X:57292497:G:GT	acceptor_gain	1.0000
X:57292497:GG:G	acceptor_gain	1.0000
X:57292497:GGT:G	acceptor_gain	1.0000
X:57292497:GGTG:G	acceptor_gain	1.0000
X:57292497:GGTGA:G	acceptor_gain	1.0000
X:57292578:CAG:C	donor_gain	1.0000
X:57292579:AGGT:A	donor_loss	1.0000
X:57292582:T:G	donor_loss	1.0000
X:57310588:CTTA:C	acceptor_loss	1.0000
X:57310589:TTA:T	acceptor_loss	1.0000
X:57310590:TAG:T	acceptor_loss	1.0000
X:57310591:A:AG	acceptor_gain	1.0000
X:57310591:A:C	acceptor_loss	1.0000
X:57310591:AG:A	acceptor_gain	1.0000
X:57310592:G:A	acceptor_gain	1.0000
X:57310592:G:GT	acceptor_gain	1.0000
X:57310592:GGT:G	acceptor_gain	1.0000
X:57310592:GGTT:G	acceptor_gain	1.0000
X:57310592:GGTTT:G	acceptor_gain	1.0000
X:57310711:G:GT	donor_gain	1.0000
X:57310727:AAGGT:A	donor_loss	1.0000
X:57310728:AGGT:A	donor_loss	1.0000
X:57310731:T:G	donor_loss	1.0000
X:57331797:TGG:T	donor_gain	1.0000

AlphaMissense

3452 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:57331746:C:A	N187K	0.997
X:57331746:C:G	N187K	0.997
X:57341325:A:T	D226V	0.997
X:57331616:G:A	G144E	0.996
X:57331714:A:C	S177R	0.996
X:57331716:T:A	S177R	0.996
X:57331716:T:G	S177R	0.996
X:57331729:T:A	W182R	0.996
X:57331729:T:C	W182R	0.996
X:57331801:A:C	S206R	0.996
X:57331803:T:A	S206R	0.996
X:57331803:T:G	S206R	0.996
X:57341336:A:C	S230R	0.996
X:57341338:C:A	S230R	0.996
X:57341338:C:G	S230R	0.996
X:57331739:C:T	S185F	0.995
X:57341324:G:C	D226H	0.995
X:57431999:T:A	W360R	0.995
X:57431999:T:C	W360R	0.995
X:57331770:C:A	N195K	0.994
X:57331770:C:G	N195K	0.994
X:57341324:G:T	D226Y	0.994
X:57341325:A:C	D226A	0.994
X:57331710:C:A	N175K	0.993
X:57331710:C:G	N175K	0.993
X:57331736:A:T	E184V	0.993
X:57331805:C:A	S207Y	0.993
X:57341271:G:A	G208D	0.993
X:57378728:C:A	R274S	0.993
X:57488909:T:A	W526R	0.993

dbSNP variants (sampled 300 via entrez): RS1000013366 (X:57150787 A>G), RS1000019058 (X:57443614 C>T), RS1000028869 (X:57329908 G>A), RS1000029782 (X:57284281 G>A), RS1000037964 (X:57330508 G>C,T), RS1000040249 (X:57330193 C>A), RS1000044651 (X:57158902 G>A,C), RS1000052415 (X:57282987 T>A), RS1000065654 (X:57373307 T>C), RS1000088464 (X:57458412 G>T), RS1000108187 (X:57273750 C>A,T), RS1000121324 (X:57402082 G>A,T), RS1000121539 (X:57165796 G>C), RS1000125428 (X:57436610 T>A), RS1000133590 (X:57418399 A>G)

Disease associations

OMIM: gene MIM:300654 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autism spectrum disorder	Limited	X-linked

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
X-linked complex neurodevelopmental disorder	Disputed	XL

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003993_41	Menarche (age at onset)	2.000000e-09
GCST007847_104	Type 2 diabetes	5.000000e-09
GCST008839_470	Height	2.000000e-29
GCST90002384_515	Hemoglobin	3.000000e-20

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0004509	hemoglobin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1628475 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 417 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL184238	URB-597	1	417

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — N-Acylethanolamine turnover

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
LY2077855	Inhibition	8.52	pIC50
OL135	Inhibition	8.4	pIC50
URB597	Inhibition	8.3	pIC50
ASP8477	Inhibition	7.24	pIC50
JNJ1661010	Inhibition	5.24	pIC50

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.30	IC50	5	nM	URB-597
7.87	IC50	13.4	nM	CHEMBL177577

PubChem BioAssay actives

2 with measured affinity, of 12 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate	1363927: Inhibition of recombinant human N-terminal FLAG-tagged/C-terminal Myc-His6 tagged FAAH2 (32 to 579 residues) expressed in COS7 cell membranes	ic50	0.0050	uM
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one	1363927: Inhibition of recombinant human N-terminal FLAG-tagged/C-terminal Myc-His6 tagged FAAH2 (32 to 579 residues) expressed in COS7 cell membranes	ic50	0.0134	uM

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	increases methylation, decreases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
ASP8477	decreases activity	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
sulforaphane	decreases expression	1
butyraldehyde	decreases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Arsenic	affects cotreatment, increases abundance, increases expression, decreases expression	1
Silicon Dioxide	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

4 unique, capped per target: 3 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2168765	Binding	Inhibition of FAAH2	Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate. — ACS Med Chem Lett
CHEMBL4626512	ADMET	Substrate activity at FAAH2 in human brain S9 fraction assessed as bezafibrate level at 100 uM measured after 15 mins by LC-MS/MS analysis	A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. — J Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder